FrançaisAre analysts right about Arcus Biosciences, Inc. (RCUS)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Arcus Biosciences, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 26% were profitable, average return +13% (69 calls). At 3 months: +5% average return (42% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| SVB Leerink | 10 | 20% | -4% |
| Citigroup | 9 | 0% | -25% |
| Wedbush | 8 | 0% | -28% |
| Cantor Fitzgerald | 8 | 25% | +1% |
| Barclays | 7 | 29% | +24% |
Frequently asked questions
Is Arcus Biosciences, Inc. a buy right now?
The analyst consensus on Arcus Biosciences, Inc. (RCUS) is "Buy" (15 bullish, 0 bearish calls over 12 months). This is not advice: historically, 26% of their targets on this stock turned out profitable over 1 year.
What is Arcus Biosciences, Inc.'s price target?
The median 12-month price target is $44.00 (+44% vs $30.59), ranging from $22.00 to $49.00 (8 analysts).
Are analysts accurate on Arcus Biosciences, Inc.?
Over 1 year, 26% of analyst targets on Arcus Biosciences, Inc. were profitable, for an average return of +13% (across 69 timestamped calls). This is JPI Invest's accuracy metric.
What is the Arcus Biosciences, Inc. stock forecast?
Analysts target a median of $44.00 within 12 months, i.e. +44% vs the current price. The most bullish targets $49.00, the most cautious $22.00.
What is the Arcus Biosciences, Inc. stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $44.00, +44%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (26%), and the stock's past trajectory.
Is Arcus Biosciences, Inc. overvalued?
Detailed valuation data for Arcus Biosciences, Inc. is available in the interactive analysis.
📊 See the full interactive analysis of Arcus Biosciences, Inc. →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.